However, compared with G-Ki67 I, G-Ki67 II had a significantly worse outcome in subgroups of patients with T stage T1, T2, N stage N0 and N1/2, and tumor stages I (P<0.05), not in stage T1/2N1/2 (P=0.051, Table 5). This evidence concerns the gene MKI67 and neoplasm.